Countering Coupons: Large Employers Will Boost Copay Accumulator Programs In 2021

Annual large US employer health benefits survey also evaluates plans for managing the cost of cell and gene therapies in the coming years, anticipating growing use of outcomes-based contracts, but very limited uptake of payment-over-time models.

Businessman hand stops domino continuous overturned meaning that hindered business failure. Stop over this business failure concept.
Payers Increasingly Seeking To Halt Use Of Manufacturer Coupons.

Nearly 50% of large US employers plan to implement copay accumulator programs in 2021 to block the impact of manufacturer-sponsored coupons, up from 39% using them in 2020, according to the Business Group on Health’s annual Health Care Strategy and Plan Design Survey, released 18 August.

Another 14% of employers said they are considering using copay accumulators during 2022-2023, the survey found. Fielded in May and...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Cell & Gene Therapies

More from Advanced Technologies